Preventing dementia

Canadian Journal of Neurological Sciences

Volumn 28, Issue SUPPL. 1, 2001, Pages

  Black, S E ^a   Patterson, C ^a   Feightner, J ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ESTROGEN; NEUROTOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; SELEGILINE;

CASE CONTROL STUDY; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DEMENTIA; DOWN SYNDROME; EDUCATION; ESTROGEN THERAPY; FAMILY HISTORY; GENE MUTATION; GENETIC PREDISPOSITION; HEAD INJURY; HUMAN; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 0035099568     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100001219     Document Type: Conference Paper

References (145)

1. Canadian study of health and aging: Study methods and prevalence of dementia
2. Pathophysiology of Alzheimer's syndrome
3. Genes and recent developments in the epidemiology of Alzheimer's disease and related dementia
4. Genetic factors in Alzheimer's disease: A review of recent advances
5. Rate of dementia of the Alzheimer type (DAT) in subjects with mild cognitive impairment
6. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study
7. Predictors of cognitive change in older persons: MacArthur studies of successful aging
8. A typology of subclinical senescent cognitive disorder
9. The radiologic prediction of Alzheimer's disease: The atrophic hippocampal formation
10. Alzheimer's disease: Longitudinal CT studies of ventricular change
11. Hippocampal formation size predicts declining memory performance in normal aging
12. Fluvoxamine in the treatment of demented elderly patients: A double-blind, placebo-controlled study
13. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia
14. The Canadian study of health and aging: Risk factors for Alzheimer's disease in Canada
15. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
16. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know and what they should know
17. Epidemiological, clinical and neuropathological study of apolipoprotein E genotype in Alzheimer's disease
18. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
19. Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences
20. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease
21. Genetic factors for the development of Alzheimer's disease in the Cherokee Indian
22. Apolipoprotein E type 4 allele and Alzheimer's disease: Effect on age at onset and relative risk in different age groups
23. ApoE-4 and age at onset of Alzheimer's disease: The NIMH genetics initiative
24. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease
25. Familial aggregation of Alzheimer's disease and related disorders: A collaborative re-analysis of case-control studies
26. Alzheimer's disease in Down's syndrome: Clinicopathologic studies
27. The epidemiology of Alzheimer's disease in intellectual disability: Results and recommendations from an international conference
28. Normal ageing in adults with Down's syndrome: A longitudinal study
29. Aging and Alzheimer's disease in Down's syndrome: Clinical and pathological changes
30. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down's syndrome
31. Very old women at highest risk of dementia and Alzheimer's disease: Incidence data from the Kungsholmen Project, Stockholm
32. Epidemiology, education and the ecology of Alzheimer's disease
33. Influence of education and occupation on the incidence of Alzheimer's disease
34. Head trauma as a risk factor for Alzheimer's disease: A collaborative re-analysis of case-control studies
35. Immunocytochemistry of neurofibrillary tangles in dementia pugilistica and Alzheimer's disease: Evidence for common genesis
36. The association between head trauma and Alzheimer's disease
37. Synergistic effects of traumatic head injury and apolipoprotein- epsilon 4 in patients with Alzheimer's disease
38. Effect of age, ethnicity and head injury on the association between ApoE genotypes and Alzheimer's disease
39. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype
40. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias
41. Head trauma and risk of dementia and Alzheimer's disease: The Rotterdam Study
42. Neurotropic viruses and Alzheimer's disease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the etiology of the disease
43. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease
44. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation
45. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study
46. Aluminum concentrations in drinking water and risk of Alzheimer's disease
47. Further thoughts on the aluminum-Alzheimer's disease link
48. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?
49. The association between aluminum-containing products and Alzheimer's disease
50. Intranuclear aluminium content in Alzheimer's disease, dialysis encephalopathy and experimental aluminium encephalopathy
51. Effect of exposure of miners to aluminium powder
52. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories
53. Intramuscular desferrioxamine in patients with Alzheimer's disease
54. Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study
55. Smoking and Alzheimer's disease: A review of the epidemiological evidence
56. Tobacco consumption and cognitive impairment in elderly people. A population-based study
57. The "protective," influence of cigarette smoking on Alzheimer's and Parkinson's diseases. Quagmire or opportunity for neuroepidemiology?
58. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam study
59. Anti-inflammatory drugs in the fight against Alzheimer's disease
60. Inflammatory processes and anti-inflamatory drugs in Alzheimer's disease: A current appraisal
61. A pilot study of prednisone in Alzheimer's disease
62. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease
63. Anti-inflammatory drugs and Alzheimer's disease
64. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study
65. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
66. Risk of Alzheimer's disease and duration of NSAID use
67. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study
68. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
69. Histamine H2 blocking drugs and the risk for Alzheimer's disease: The Rotterdam Study
70. Central analgesic effects of aspirin-like drugs
71. Clinical trial of indomethacin in Alzheimer's disease
72. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
73. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study
74. The neuroendocrinology of stress and aging: The glucocortocoid cascade hypothesis
75. The effect on memory of chronic prednisone treatment in patients with systemic disease
76. New therapeutic approaches to Alzheimer's disease
77. The estrogen/neurotrophin connection during neural development: Is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant?
78. 17-b estradiol protects neurons from oxidative stress-induced cell death in vitro
79. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia?
80. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor
81. Estrogen and nerve growth factor-related systems in brain. Effects on basal forebrain cholinergic neurons and implications for learning and memory processes and aging
82. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells
83. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein
84. Estrogen control of central neurotransmission: Effect on mood, mental state and memory
85. Lack of postmenopausal estrogen replacement therapy and the risk of dementia
86. Suranyi-Cadotte BE. Up-regulatory effect of estrogen on platelet 3H-Imipramine binding sites in surgically menopausal women
87. Sex hormones and psychological functioning in postmenopausal women
88. Cognitive pattern in men and women is influenced by fluctuations in sex hormones
89. Estrogenic effects on memory in women
90. Effects of estrogen on memory function in surgically menopausal women
91. Lifetime estrogen exposure and cognitive performance in elderly women
92. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia
93. Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study
94. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study
95. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects
96. Estrogen deficiency and risk of Alzheimer's disease in women
97. Estrogen replacement therapy and risk of Alzheimer's disease
98. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
99. The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature
100. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease
101. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study
102. Assessing the use of medications in the elderly: Methods and initial experience in the Cardiovascular Health Study
103. The occurrence of depressive symptoms in the preclinical phase of AD: A population-based study
104. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community
105. Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area
106. Prevention of vascular dementia
107. Blood pressure lowering for the prevention of cognitive decline in patients with cerebrovascular disease
108. Brain infarction and the clinical expression of Alzheimer's disease
109. Status of risk factors for dementia associated with stroke
110. Risk of dementia after stroke in a hospitalized cohort: Results of a longitudinal study
111. Aetiological considerations and risk factors for multi-infarct dementia
112. The Canadian Study of Health and Aging: Risk factors for vascular dementia
113. Clinical-neuropathologic findings in multi-infarct dementia: A report of six autopsied cases
114. Antihypertensive drugs, brain structure and cognitive function: More research is necessary
115. Calcium-channel blockers and cognitive function in elderly people: Results from the Canadian Study of Health and Aging
116. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment
117. CT in the differential diagnosis between Alzheimer's disease and vascular dementia
118. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial
119. Reduction of dementia by calcium-antagonist-based antihypertensive treatment
120. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
121. Vascular aspects in Alzheimer's disease
122. A randomized trial of aspirin and sulfinpyrazone in threatened stroke
123. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
124. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke
125. Collaborative overview of randomized trials of antiplatelet therapy, I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
126. The Canadian American Ticlopidine study (CATS) in thromboembolic stroke
127. A randomised, blinded, trial of clopidogrel versus asprin in patients at risk of ischaemic events (CAPRIE)
128. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
129. Stroke prevention in nonvalvular atrial fibrillation: A review of prospective randomized trials
130. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis
131. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators
132. Endarterectomy for asymptomatic carotid artery stenosis
133. European pentoxifylline multi-infarct dementia study
134. Mental deterioration in old age: Results of two multicenter, clinical trials with nimodipine
135. Overview of clinical trials of hydergine in dementia
136. Clinical trials in dementia with propentofylline
137. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia
138. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study
139. Vascular-induced disorders of cerebral performance in the elderly. Long-term therapy with pentoxifylline and psychological mental training
140. Vitamin E and Alzheimer's disease: The basis for additional clinical trials
141. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
142. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia
143. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
144. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)